<?xml version="1.0" encoding="UTF-8"?>
<p id="p0150">
 <italic>BNT162 (a1, b1, b2, c2)</italic> from BioNTech is another lipid nanoparticle mRNA vaccine and has received clearance from regulatory authority form Germany to the start of phase I-II trials on 196 volunteers. The trial is dose escalation design (1â€“100 mcg) using 4 vaccine subtypes (a1, b1, b2, and c2). The developers have claimed to have an emergency-use vaccine by September 2020.
 <xref rid="bib80" ref-type="bibr">
  <sup>80</sup>
 </xref>
</p>
